Three companies add new drugs

The TGA has approved three new products - Chiesi’s Filsuvez, Seqirus’ Ryaltris Allergy, and Specialised Therapeutics’ Niktimvo – plus a subcutaneous version of AstraZeneca’s Saphnelo.

Filsuvez is a topical gel indicated for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients six months and older while Ryaltris Allergy is indicated for the treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis for up to six months in adults and children 12 years of age and over.

Ryaltris Allergy joins Seqirus’ existing brand Ryaltris which is indicated for patients six years of age and older.